血管外植入式心律转复除颤器一年真实世界经验:Enlighten上市后注册研究
Enlighten为前瞻性全球真实世界注册研究,纳入787例尝试植入EV-ICD的患者,1年无系统或操作相关重大并发症率为89.1%(95%CI 86.3%-91.3%),首次恰当治疗率7.3%(95%CI 5.5-9.6),自发性放电成功率100%(61/61),单形性室速抗心动过速起搏成功率74.2%,首次不恰当放电率7.1%(95%CI 5.4-9.4)。
要点
- EV-ICD在真实世界中1年无重大并发症率为89.1%,与上市前试验一致。
- 自发性室速/室颤放电成功率100%,单形性室速抗心动过速起搏成功率74.2%。
- 首次不恰当放电率7.1%,非心脏过感知为主要原因(占不恰当放电事件的40.5%)。
核心结论
- 在迄今最大的全球EV-ICD前瞻性队列中,抗心动过速起搏和放电治疗均有效,1年重大并发症率与上市前经验一致。
研究设计与样本
- Enlighten为前瞻性、全球、真实世界注册研究,纳入787例尝试植入EV-ICD的患者(49.1±15.2岁,28.7%女性,34.1%二级预防),由168名植入者操作。
主要发现
- 781/787例(99.2%)成功完成胸骨下隧道和导线放置,758例(96.3%)在除颤和电学测试后保持植入。
- 1年无系统或操作相关重大并发症率为89.1%(95%CI 86.3%-91.3%)。
- 1年首次恰当治疗(放电、抗心动过速起搏或两者)率为7.3%(95%CI 5.5-9.6)。
- 自发性离散事件放电成功率为100%(61/61),单形性室速抗心动过速起搏成功率(广义估计方程)为74.2%。
- 1年首次不恰当放电率为7.1%(95%CI 5.4-9.4),非心脏过感知为主要原因(占不恰当放电事件的40.5%)。
临床怎么用
- EV-ICD可在真实临床实践中提供有效的除颤和抗心动过速起搏治疗,且不占用血管内路径。
- 需关注非心脏过感知导致的不恰当放电,优化感知鉴别设置可能有助于减少此类事件。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The extravascular implantable cardioverter defibrillator (EV-ICD) was developed to provide defibrillation and antitachycardia pacing therapy without the need for intravascular lead placement. Premarket clinical trials reported EV-ICD safety and efficacy through 3 years, but a real-world assessment of the Aurora EV-ICD system, which includes a novel sensing discriminator, is needed. The objective of this analysis was to assess real-world therapy efficacy and safety of the EV-ICD through 1 year. METHODS: Enlighten: The EV-ICD Post Approval Registry is a prospective, global, real-world registry that included patients who underwent an EV-ICD implantation attempt. The main safety analysis was freedom from all system- or procedure-related major complications through 1 year. Event rates at 1 year were calculated using the Kaplan-Meier method. RESULTS: EV-ICD system implantation was attempted by 168 implanters in 787 patients (49.1±15.2 years old; 28.7% women; 34.1% secondary prevention). Tunneling and lead placement in the substernal space were achieved in 781 of 787 patients (99.2%), with 758 patients (96.3%) remaining implanted following defibrillation and electrical testing. One-year freedom from major system- or procedure-related complications was 89.1% (95% CI, 86.3%-91.3%). The 1-year rate of first appropriate therapy (shock, antitachycardia pacing, or both) was 7.3% (95% CI, 5.5-9.6). Shock success for discrete spontaneous episodes was 100% (61 of 61), and the generalized estimating equations antitachycardia pacing success rate, to account for multiple episodes per patient, was 74.2% for monomorphic ventricular tachycardia. The 1-year rate of first inappropriate shock was 7.1% (95% CI, 5.4-9.4), with noncardiac oversensing as the main cause (40.5% of inappropriately shocked episodes). CONCLUSIONS: In the largest prospective worldwide cohort of patients with an EV-ICD to date, both antitachycardia pacing and shock therapy were effective, while the rate of major complications agreed with the premarket experience through 1 year. These data demonstrate that positive outcomes of the EV-ICD are retained in everyday clinical practice in a large, global cohort with an expanded number of implanters. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06048731.
引用
- Boersma LVA, Amin A, Murgatroyd F, et al. Real-World Experience With the Extravascular Implantable Cardioverter Defibrillator Through 1 Year: The Enlighten Post Approval Registry Study. Circulation. 2026. PMID: 42770223. doi:10.1161/CIRCULATIONAHA.126.080942
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。